结/直肠癌的潜在治疗靶点  

Potential Therapeutic Targets for Colorectal Cancer

作　　者：孙阳[1,2] 孟瑾[1,3] 樊磊[1] 李倩[1] 张欣[2] 张恩户[2] 梅其炳[1] 

机构地区：[1]第四军医大学药学系药理教研室中药胃肠药理重点研究室国家中医药管理局重点研究室,陕西西安710032 [2]陕西中医学院药理教研室,陕西咸阳712046 [3]解放军第309医院药剂科,北京100091

出　　处：《现代生物医学进展》2013年第5期966-969,共4页Progress in Modern Biomedicine

基　　金：国家科技部973计划前期研究专项(2010CB535002);陕西省科技厅研究专项(2010ZDKG-47)

摘　　要：传统的结/直肠癌化疗药物,作用选择性较低,副反应明显,疗效欠佳,患者病死率居高不下。寻找新型治疗药物,十分必要。在结/直肠癌发病机制的探索过程中,研究者发现:一些分子的变化影响着疾病进程,对病情起指示作用,有可能成为治疗靶点。围绕这些分子设计药物,制定治疗方案,有望提高疗效,改善病人生存质量,降低不良反应的发生。本文就结/直肠癌的部分潜在治疗靶点:EGFR,VEGF,HADC,COX-2,PPARγ及galectin-3做一综述。The traditional chemotherapy drugs of colorectal cancer（CRC）,with a comparatively low selectivity for tissues and many side effects,are not satisfied in the treatment for CRC;the mortality of CRC still remains high.The search for new drugs,therefore,is needed.In the course of elucidating the pathogenesis of CRC,researchers found that： some molecules,which act as indictors of the progression of CRC,can affect the disease process and may become therapeutic targets.Around these molecules,there is hope that new drugs and treatment plans will be developed to improve efficacy,quality of life of patients and reduce adverse reactions.In this paper,some of the potential targets,including EGFR,VEGF,HADC,COX-2,PPARγ and galectin-3 were reviewed.

关 键 词：结肠癌 直肠癌 EGFR VEGF HADC COX-2 PPARΓ GALECTIN-3 

分 类 号：R735.3[医药卫生—肿瘤]